Ticker Notes
A collection of stock notes from around the web.
April 15, 2009
6.50 Price Target on ZymoGenetics
Zacks has a
$6.50 price target
on ZymoGenetics, sighting the recent approval of
of rhThrombin by the FDA. That is slightly more than double the current price.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment